C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
A holder of C4 Therapeutics, Inc. (CCCC) common stock filed a Form 144 notice to sell up to 19,519 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $76,680.39, in connection with a stock option exercise for cash expected on August 12, 2026. The notice also reports that Mark Mossler previously sold 9,087 shares of common stock on May 27, 2026 for an aggregate market value of $35,484.74.
Morgan Stanley and its affiliates reported updated ownership of C4 Therapeutics, Inc. common stock on Schedule 13G/A (Amendment No. 3). Morgan Stanley reported beneficial ownership of 8,862,002 shares of C4 Therapeutics common stock, representing 8.0% of the outstanding class.
Morgan Stanley Capital Services LLC reported beneficial ownership of 8,718,000 shares, or 7.9%, all with shared voting and dispositive power. Morgan Stanley & Co. LLC reported 134,047 shares, or 0.1%, and stated that it has ceased to be the beneficial owner of more than five percent of this class of securities.
C4 Therapeutics reported unaudited results for the quarter ended June 30, 2026, remaining a clinical-stage company with no product sales and revenues derived from collaborations. Revenue from collaboration agreements was $6.6 million in the quarter and $12.8 million for the first half of 2026.
The company recorded a quarterly net loss of $23.6 million and a six‑month net loss of $48.8 million, with operating expenses driven mainly by research and development of its degrader pipeline, including lead program cemsidomide for multiple myeloma and CFT8919 for EGFR‑mutant lung cancer.
Liquidity remains strong, with $300.4 million in cash, cash equivalents, and marketable securities and total assets of $359.4 million as of June 30, 2026. Management states this resource base is expected to fund operations for at least twelve months. A new Roche degrader‑antibody conjugate collaboration added a $20.0 million upfront payment and significant potential milestones and royalties, supplementing existing partnerships with MKDG, Betta Pharma, Roche, Biogen, and Pfizer.
C4 Therapeutics, Inc. reported second quarter 2026 results and provided clinical and corporate updates centered on its IKZF1/3 degrader cemsidomide. For the quarter ended June 30, 2026, revenue from collaboration agreements was $6.6 million, while research and development expense was $24.5 million and general and administrative expense was $8.6 million. Net loss was $23.6 million, or $0.18 per share.
Cash, cash equivalents and marketable securities totaled $300.4 million as of June 30, 2026, supported by a $20 million upfront payment from a new collaboration with Roche and $33.5 million in net proceeds raised through an at-the-market program. The company expects this cash to fund operations through the end of 2028.
Clinically, a Phase 2 multiple myeloma trial of cemsidomide plus dexamethasone is ongoing, with enrollment expected to complete in early 2027 and initial overall response rate data in the second half of 2027. A Phase 1b trial in combination with elranatamab is progressing, and another Phase 1b trial with standard-of-care multiple myeloma therapies is planned to initiate in the first half of 2027.
BlackRock, Inc., through certain of its business units and affiliates, reports beneficial ownership of 7,678,906 shares of C4 Therapeutics, Inc. common stock, representing 6.9% of the class as of June 30, 2026.
BlackRock has sole voting power over 7,586,715 shares and sole dispositive power over 7,678,906 shares, with no shared voting or dispositive power. Various underlying clients and accounts have rights to dividends and sale proceeds, but no single person has more than five percent of C4 Therapeutics’ outstanding common shares.
C4 Therapeutics, Inc. reported equity compensation activity for Chief Medical Officer Leonard Reyno. On July 10, 2026, Reyno acquired 15,325 shares of common stock upon vesting of previously granted restricted stock units. In a related move, 7,397 shares were withheld by the company to cover tax obligations associated with this vesting, which the company states does not represent an open-market sale.
Anderson Kenneth Carl reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics, Inc. director Kenneth C. Anderson received an equity award of common stock rather than cash fees for his board service. On July 1, 2026, he was granted 2,650 shares at a value based on the closing market price of $4.34 per share, in line with the company’s Non-Employee Director Compensation Policy. Following this compensation grant, Anderson directly holds 71,950 common shares. Additional shares are held indirectly through several Anderson family revocable and irrevocable trusts, for which he disclaims beneficial ownership except for any pecuniary interest.
GROGAN DONNA ROY reported acquisition or exercise transactions in this Form 4 filing.
C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares were issued under the company’s Non-Employee Director Compensation Policy, as she elected stock instead of cash fees, bringing her direct holdings to 74,853 shares.
C4 Therapeutics, Inc. director Owen Hughes received a grant of stock options covering 62,000 shares of common stock. The options have an exercise price of $4.2500 per share and expire on June 23, 2036. Following this grant, Hughes holds options on 62,000 shares directly.
According to the vesting terms, the option becomes fully exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, provided Hughes continues serving on the Board through that date.
C4 Therapeutics, Inc. director Steven L. Hoerter received a grant of stock options covering 62,000 shares of Common Stock. The options have an exercise price of $4.25 per share and expire on June 23, 2036.
According to the footnote, the entire option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s next annual stockholder meeting, assuming he continues to serve on the Board through that date. After this grant, he holds 62,000 options directly.